Kodiak Pharma - חוב כולל להון KOD

Revitalizing its ophthalmology pipeline through a series of new studies, Kodiak Sciences Inc. demonstrates a trend where the equity leverage ratio is available in the GURU.Markets terminal, and the parameter value equals 2.44. The company is implementing an innovative ABC platform for long-term eye treatment, thereby creating a sustainable sales stream through the therapy of chronic ailments.

Kodiak Sciences Inc. (KOD) invests in the development of innovative biologics for the therapy of retinal diseases. The total debt-to-equity ratio measures the proportion of borrowed funds relative to the company's own assets. This indicator allows for an assessment of financial stability and bankruptcy risk during the scaling of development. By analyzing the history of the total debt-to-equity ratio, an investor determines the degree of the business's dependence on creditors. A decrease in this metric confirms the strengthening of the issuer's fundamental base.